Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease

Hadar Haim-Pinhas, Gil Yoskovitz, Michael Lishner, David Pereg, Yona Kitay-Cohen, Guy Topaz, Yaron Sela, Ori Wand, Ilan Rozenberg, Sydney Benchetrit, Keren Cohen-Hagai*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic kidney disease is associated with an increased risk for cardiovascular and bleeding events. Data regarding the effectiveness and risks of aspirin therapy for primary prevention in the high-risk group of patients with chronic kidney disease are scant and controversial. This retrospective study included patients with chronic kidney disease. Participants were divided according to aspirin use. Outcomes included non-fatal cardiovascular events, major bleeding events and all-cause mortality. Among 10,303 patients, 2169 met the inclusion criteria and 1818 were included after 1:1 propensity-score matching. Our final cohort included patients with mean age of 73.4 ± 11.6 years, estimated glomerular filtration rate of 31.5 ± 10.5 ml/min/1.73m2 with follow up of 4.9 ± 1.5 years. There were no significant differences in all-cause mortality and bleeding events (odds ratio = 1.03, confidence interval [0.62, 1.84], p =.58 and odds ratio = 1.09, confidence interval [0.65, 1.72], p =.87 respectively). The incidence of cardiovascular events was higher in aspirin users versus non-users on univariate analysis (p < 0.01) and was comparable after controlling for possible risk-factors (OR = 1.05, CI [0.61, 3.14], p =.85). Chronic aspirin use for primary prevention of cardiovascular disease was not associated with lower mortality, cardiovascular events or increased bleeding among patients with chronic kidney disease. Those results were unexpected and should prompt further research in this field.

Original languageEnglish
Article number17788
JournalScientific Reports
Volume12
Issue number1
DOIs
StatePublished - Dec 2022

Fingerprint

Dive into the research topics of 'Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this